Share-based Payment Arrangement, Expense of Cerevel Therapeutics Holdings, Inc. from 31 Dec 2019 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Cerevel Therapeutics Holdings, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2019 to 31 Mar 2024.
  • Cerevel Therapeutics Holdings, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Mar 2024 was $20,932,000, a 66% increase year-over-year.
  • Cerevel Therapeutics Holdings, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Mar 2024 was $77,750,000, a 82% increase year-over-year.
  • Cerevel Therapeutics Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $69,410,000, a 79% increase from 2022.
  • Cerevel Therapeutics Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $38,780,000, a 62% increase from 2021.
  • Cerevel Therapeutics Holdings, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $23,941,000, a 128% increase from 2020.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Cerevel Therapeutics Holdings, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $77,750,000 $20,932,000 +$8,340,000 +66% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2024 2024 Q1
Q4 2023 $69,410,000 $25,222,000 +$14,844,000 +143% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2024 2023 FY
Q3 2023 $54,566,000 $17,088,000 +$7,392,000 +76% 01 Jul 2023 30 Sep 2023 10-Q 01 Nov 2023 2023 Q3
Q2 2023 $47,174,000 $14,508,000 +$4,360,000 +43% 01 Apr 2023 30 Jun 2023 10-Q 02 Aug 2023 2023 Q2
Q1 2023 $42,814,000 $12,592,000 +$4,034,000 +47% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $38,780,000 $10,378,000 +$3,892,000 +60% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2024 2023 FY
Q3 2022 $34,888,000 $9,696,000 +$3,562,000 +58% 01 Jul 2022 30 Sep 2022 10-Q 01 Nov 2023 2023 Q3
Q2 2022 $31,326,000 $10,148,000 +$4,964,000 +96% 01 Apr 2022 30 Jun 2022 10-Q 02 Aug 2023 2023 Q2
Q1 2022 $26,362,000 $8,558,000 +$2,421,000 +39% 01 Jan 2022 31 Mar 2022 10-Q 03 May 2023 2023 Q1
Q4 2021 $23,941,000 $6,486,000 +$5,830,000 +889% 01 Oct 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
Q3 2021 $18,111,000 $6,134,000 +$2,662,000 +77% 01 Jul 2021 30 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $15,449,000 $5,184,000 +$1,761,000 +51% 01 Apr 2021 30 Jun 2021 10-Q 01 Aug 2022 2022 Q2
Q1 2021 $13,688,000 $6,137,000 +$3,167,000 +107% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q4 2020 $10,521,000 $656,000 01 Oct 2020 31 Dec 2020 10-K 22 Feb 2023 2022 FY
Q3 2020 $3,472,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $3,423,000 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021 2021 Q2
Q1 2020 $2,970,000 01 Jan 2020 31 Mar 2020 10-Q 17 May 2021 2021 Q1

Cerevel Therapeutics Holdings, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $69,410,000 +$30,630,000 +79% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2024 2023 FY
2022 $38,780,000 +$14,839,000 +62% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2024 2023 FY
2021 $23,941,000 +$13,420,000 +128% 01 Jan 2021 31 Dec 2021 10-K 27 Feb 2024 2023 FY
2020 $10,521,000 +$2,210,000 +27% 01 Jan 2020 31 Dec 2020 10-K 22 Feb 2023 2022 FY
2019 $8,311,000 01 Jan 2019 31 Dec 2019 10-K 01 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.